Nivestim(TM), a New Biosimilar Filgrastim, is Approved in Europe for the Prevention of Febrile Neutropenia Associated With Chemotherapy

Nivestim(TM), Hospira's filgrastim, has received approval from the European Commission (EC) for the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced neutropenia (CIN)

LEAMINGTON SPA, England, June 10, 2010 - Hospira announced today that the EC has approved Nivestim(TM)
(filgrastim) for the prevention of FN, the most serious haematological
toxicity that occurs as a result of cancer chemotherapy(1). Nivestim now has
marketing authorisation in all EU member states. Nivestim is expected to
reduce the cost of neutropenia treatment.

Dr Cornelius Waller, Associate Professor of Internal Medicine at the
Freiburg University Medical Center, Germany, said: "The approval of Nivestim
offers tangible benefits to healthcare professionals and patients alike.
Neutropenia that occurs as a result of cancer chemotherapy can result in
patients being unable to complete their full course of chemotherapy. Nivestim
provides healthcare professionals with a cost-effective, easy-to-use option
to keep patients on track."

Nivestim is Hospira's second biosimilar. The company's biosimilar
erythropoietin, Retacrit(TM), is currently available in 17 European
countries, and Hospira is the first US-headquartered company to market
biosimilar drugs in Europe. The company's biosimilar pipeline, one of the
largest in the industry, also includes pegfilgrastim, a longer-acting version
of filgrastim.

"As part of Hospira's continued commitment to expand its biosimilar
portfolio, we are proud to announce that Nivestim has received licence
approval from the EC," said Ron Squarer, chief commercial officer, Hospira.
"Nivestim addresses unmet needs of patients and healthcare professionals
through a unique combination of features that enhance convenience and safety,
while reducing the cost of treatments."

Nivestim is a new filgrastim available in three presentations - 48 MU
(480 mcg), 30 MU (300 mcg) and the unique 12 MU (120 mcg) low weight
presentation. All presentations are available in a pre-filled syringe,
allowing patients to self-administer Nivestim at home, thus conserving
valuable healthcare resources. Each syringe has an integrated needle-safe
device to facilitate safer administration and is individually blister-packed
to reduce the risk of contamination and provide tamper-evidence.

In a large, randomised Phase lll study, Nivestim demonstrated comparable
efficacy to Neupogen(R) in the prevention of FN, and was as well tolerated,
with a similar adverse event profile.(2)

Notes to Editors:

About Hospira

Hospira is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness(TM). As the world leader in specialty
generic injectable pharmaceuticals, Hospira offers one of the broadest
portfolios of generic acute-care and oncology injectables, as well as
integrated infusion therapy and medication management solutions. Through its
products, Hospira helps improve the safety, cost and productivity of patient
care. The company is headquartered in Lake Forest, Illinois, United States
and has approximately 13,500 employees. The head office for Hospira in
Europe, Middle East and Africa is in Leamington Spa, UK. Learn more at
www.hospira.com.

References:

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced Neutropenia:
Risks, Consequences, and New Directions for Its Management. Cancer, 2004;
100(2): 228-37

2. Waller, CF et al. Biosimilar filgrastim is an effective primary
prophylactic therapy for neutropenia in patients (pts) receiving doxorubicin
and docetaxel (AT) for breast cancer (BC). Poster presentation at the joint
ECCO 15 and 34th ESMO Multidisciplinary Congress: Abstract E15-1238, 2009.

European Media, Hannah Stacey of Athena, +44-020-8956-2289, +44-07984-496-441; or U.S. Media, Dan Rosenberg, +1-224-212-3366, or Investors, Karen King, +1-224-212-2711, both of Hospira